Psilocybin-Assisted Treatment of Depression, Anxiety and Substance use Disorders: Neurobiological Basis and Clinical Application

被引:0
|
作者
Lasch, Anna [1 ]
Schweikert, Timo [2 ]
Dora, Eva [1 ]
Kolb, Theresa [3 ]
Schurig, Hanne Lilian [3 ,5 ]
Walther, Andreas [4 ]
机构
[1] Tech Univ Dresden, Biopsychol, Dresden, Germany
[2] Justus Liebig Univ Giessen, Psychotherapie & Systemneurowissensch, Giessen, Germany
[3] Univ klinikum Carl Gustav Carus Dresden, Div Psychol & Social Med & Dev Neurosci, Dresden, Germany
[4] Univ Zurich Psychol Inst, Klin Psychol Psychotherapie, Zurich, Switzerland
[5] Univ klinikum Carl Gustav Carus Dresden, Psychosoziale Med & Entwicklungsneurowissensch, D-01307 Dresden, Germany
关键词
Psilocybin; therapy; depression; neurobiology; 5-HT-2A receptor; terminal diseases; MYSTICAL-TYPE EXPERIENCES; LIFE-THREATENING CANCER; MODE NETWORK ACTIVITY; FUNCTIONAL CONNECTIVITY; PSYCHEDELIC DRUGS; BRAIN; SEROTONIN; PSYCHOTHERAPY; AMYGDALA; MODULATION;
D O I
10.1055/a-2046-5202
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Successful therapy of mental disorders is very important in view of the high level of suffering of those affected. Since established pharmaceutical and psychotherapeutic approaches do not lead to the desired improvement in all cases, complementary or alternative treatment methods are intensively researched. Psilocybin-assisted psychotherapy seems particularly promising, and has been approved in the USA for larger clinical trials. Psilocybin belongs to the group of psychedelics and influences psychological experiences. In assisted therapy, psilocybin is administered in controlled doses under medical supervision to patients with different mental disorders. In the studies conducted so far, longer-term positive effects could be shown after just one or a few doses. In order to provide a better understanding of the potential therapeutic mechanisms, this article will first describe neurobiological and psychological effects of psilocybin. To better assess the potential of psilocybin-assisted psychotherapy for various disorders, clinical studies conducted so far with patients administered psilocybin are reviewed.
引用
收藏
页码:230 / 245
页数:16
相关论文
共 50 条
  • [21] Psilocybin-assisted psychotherapy for treatment-resistant depression: A phase II, randomized, feasibility study
    Rosenblat, Joshua
    McIntyre, Roger
    BIPOLAR DISORDERS, 2023, 25 : 44 - 44
  • [22] Clinical Outcomes of an Integrated Treatment for Depression and Substance Use Disorders
    Lydecker, Katherine P.
    Tate, Susan R.
    Cummins, Kevin M.
    McQuaid, John
    Granholm, Eric
    Brown, Sandra A.
    PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2010, 24 (03) : 453 - 465
  • [23] Depression, anxiety and substance use disorders and their relation with the workplace
    Langlieb, Alan M.
    INTERNATIONAL JOURNAL OF PSYCHOLOGY, 2008, 43 (3-4) : 385 - 385
  • [24] Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism?
    Roth R.M.
    Brunette M.F.
    Green A.I.
    Current Psychiatry Reports, 2005, 7 (4) : 283 - 291
  • [25] Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome
    Howland, Robert H.
    Rush, A. John
    Wisniewski, Stephen R.
    Trivedi, Madhukar H.
    Warden, Diane
    Fava, Maurizio
    Davis, Lori L.
    Balasubramani, G. K.
    McGrath, Patrick J.
    Berman, Susan R.
    DRUG AND ALCOHOL DEPENDENCE, 2009, 99 (1-3) : 248 - 260
  • [26] Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial
    Rieser, Nathalie M.
    Bitar, Raoul
    Halm, Simon
    Rossgoderer, Christina
    Gubser, Ladina P.
    Thevenaz, Maeva
    Kreis, Yara
    von Rotz, Robin
    Nordt, Carlos
    Visentini, Monika
    Moujaes, Flora
    Engeli, Etna J. E.
    Ort, Andres
    Seifritz, Erich
    Vollenweider, Franz X.
    Herdener, Marcus
    Preller, Katrin H.
    ECLINICALMEDICINE, 2025, 82
  • [27] Neuroscientific Basis of Treatment for Substance Use Disorders
    Bozkurt, Muge
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2022, 59 : 75 - 80
  • [28] Neurobiological markers predicting treatment response in anxiety disorders: A systematic review and implications for clinical application
    Lueken, Ulrike
    Zierhut, Kathrin C.
    Hahn, Tim
    Straube, Benjamin
    Kircher, Tilo
    Reif, Andreas
    Richter, Jan
    Hamm, Alfons
    Wittchen, Hans-Ulrich
    Domschke, Katharina
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2016, 66 : 143 - 162
  • [29] Major Depression in Comorbidity with Substance use Disorders: Patients' Features and Clinical-Neurobiological Rationale of Antidepressant Treatments
    De Filippis, Sergio
    Martinotti, Giovanni
    Nicoletti, Ferdinando
    Mastrostefano, Andrea
    Trovini, Giada
    Pugliese, Anna
    Di Nicola, Marco
    CURRENT NEUROPHARMACOLOGY, 2025, 23 (03) : 256 - 275
  • [30] It's time to take psilocybin seriously as a possible treatment for substance use disorders
    Bogenschutz, Michael P.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2017, 43 (01): : 4 - 6